Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price target lowered by equities research analysts at BMO Capital Markets from $102.00 to $101.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a "market perform" rating on the medical equipment provider's stock. BMO Capital Markets's price target indicates a potential downside of 0.20% from the company's previous close.
Several other equities analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Saturday. Sanford C. Bernstein increased their price target on Zimmer Biomet from $93.00 to $107.00 and gave the company a "market perform" rating in a research note on Thursday, November 5th. Truist Financial set a $114.00 price objective on Zimmer Biomet in a research report on Thursday, November 5th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, November 4th. Finally, UBS Group upped their target price on Zimmer Biomet from $120.00 to $130.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Seven research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $113.79.
Check Out Our Latest Stock Analysis on Zimmer Biomet
Zimmer Biomet Stock Down 1.9%
Shares of NYSE:ZBH traded down $2.01 during midday trading on Monday, hitting $101.20. The stock had a trading volume of 1,139,404 shares, compared to its average volume of 2,256,248. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $112.54. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 0.49. The business's 50-day simple moving average is $95.76 and its 200-day simple moving average is $92.57. The company has a market cap of $19.15 billion, a P/E ratio of 25.69, a PEG ratio of 2.42 and a beta of 0.50.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. During the same period in the prior year, the firm posted $1.90 earnings per share. The company's quarterly revenue was up 3.1% compared to the same quarter last year. On average, sell-side analysts forecast that Zimmer Biomet will post 8.56 earnings per share for the current fiscal year.
Insider Transactions at Zimmer Biomet
In other news, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by insiders.
Institutional Trading of Zimmer Biomet
A number of hedge funds have recently made changes to their positions in ZBH. BlackRock Inc. bought a new position in shares of Zimmer Biomet in the second quarter worth about $1,344,282,000. State Street Corp increased its holdings in Zimmer Biomet by 0.6% during the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider's stock worth $766,343,000 after purchasing an additional 52,044 shares during the period. Primecap Management Co. CA purchased a new position in Zimmer Biomet during the 2nd quarter worth $328,578,000. Dimensional Fund Advisors LP increased its holdings in Zimmer Biomet by 1.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider's stock worth $201,082,000 after purchasing an additional 24,208 shares during the period. Finally, Bank of America Corp DE bought a new stake in Zimmer Biomet during the 2nd quarter valued at $187,480,000. 88.89% of the stock is owned by institutional investors.
About Zimmer Biomet
(
Get Free Report)
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.